Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1661-4917
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model ; volume:70 ; number:1 ; day:17 ; month:8 ; year:2022 ; pages:1-15 ; date:12.2022
Archivum immunologiae et therapiae experimentalis ; 70, Heft 1 (17.8.2022), 1-15, 12.2022
- Urheber
-
Siemionow, Maria
Brodowska, Sonia
Langa, Paulina
Zalants, Kristina
Kozlowska, Katarzyna
Grau-Kazmierczak, Wictoria
Heydemann, Ahlke
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00005-022-00656-7
- URN
-
urn:nbn:de:101:1-2022110421441617938468
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Siemionow, Maria
- Brodowska, Sonia
- Langa, Paulina
- Zalants, Kristina
- Kozlowska, Katarzyna
- Grau-Kazmierczak, Wictoria
- Heydemann, Ahlke
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Deletion pattern in the dystrophin gene in Duchenne muscular dystrophy patients in northeast India
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Deletion pattern in the dystrophin gene in Duchenne muscular dystrophy patients in northeast India
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy